Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

This analysis focuses on comparing both early onset and late onset bortezomib-induced peripheral neuropathy to vincristine-induced peripheral neuropathy. When a myeloma patient has dose-limiting based toxicity due to bortezomib, bortezomib-induced peripheral neuropathy may result, negatively impacting a patient.

Authors:

Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P

Click here to view article:

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.